Coverage strategy · from the 250-topic plan
The employer lane: getting GLP-1 coverage through the people who actually decide
The most under-used fact in GLP-1 coverage: for the majority of Americans with job-based insurance, the employer — not the insurer — decides whether weight-management drugs are covered, because most large plans are self-funded (the carrier processes claims; the company pays them and writes the rules). That converts “my insurance excluded it” from a verdict into an address: HR and the benefits committee. The lane: read your plan documents to confirm the exclusion and the funding type; route requests through open-enrollment timing and formulary-exception machinery; make the case in the employer's own currency (competitor benchmarking, retention, the comorbidity math its health spend already pays for); and run the appeal anatomy in parallel for individual exceptions. If the answer stays no, the cash bridge — the audited $119–$139 floors with HSA/FSA pre-tax treatment — keeps therapy running while the lane works. The whole route, below.
Who actually decides — the self-funded fork
Two plan species wear the same insurance card. Fully-insured plans (common at smaller employers): the carrier sets covered benefits under state insurance rules — your appeal really is with the insurer. Self-funded plans (the large-employer norm): the company bears the claims and chooses the benefit design; the “insurer” on your card is an administrator executing your employer's choices — including the weight-management-drug exclusion many plans still carry as a line-item cost decision. The fork determines your entire strategy, and finding your species takes one question to HR (“is our plan self-funded?”) or one look at the plan documents below. For self-funded members, every “not covered” is provisional: it's a policy your employer wrote and can rewrite.
Reading your plan documents
Three artifacts, all yours by right: the Summary Plan Description (SPD) — the governing document, searchable for “weight,” “obesity,” “anti-obesity medication,” and “exclusions”; the formulary — where Zepbound and Wegovy either appear with tiers and prior-auth flags or don't appear at all (absence + SPD exclusion = a design decision, not a paperwork failure); and the prior-authorization criteria for covered drugs — BMI thresholds, comorbidity requirements, step-therapy — which script your clinician's letter per the anatomy. Capture what you find; benefits language moves, and dated screenshots make later conversations concrete. Note the adjacent lane while you're in there: many plans that exclude weight-management drugs still cover the same molecules for diabetes — a distinction that matters for anyone whose chart carries the diagnosis and a reason coverage questions belong with your prescriber, never with creative coding.
Making the ask — timing and machinery
Three channels, run together. The benefits request: a written note to HR/benefits asking whether anti-obesity-medication coverage has been evaluated for the next plan year — timed to the design cycle (decisions for January typically firm up in late summer and fall), signed by more than one employee where possible: benefits teams count requests, and five colleagues asking is a data point where one is an anecdote. The formulary-exception request: for covered-category-but-excluded-drug situations, the administrator's exception process plus your clinician's medical-necessity letter — the individual lane that sometimes opens while the policy lane grinds. The wellness-program door: a growing set of employers cover GLP-1s through contracted weight-management programs rather than the open formulary — ask specifically whether such a program exists or is under evaluation, because the answer is sometimes “yes, starting next quarter” and nobody announced it.
The business case, honestly framed
Benefits committees answer to budgets, so speak budget — without overclaiming. The defensible points: the spend already exists — the plan is currently paying for obesity's downstream claims (the diabetes, cardiovascular, apnea, and joint lines these drugs' trials touch: SELECT's cardiac file, the OSA approval, the kidney data); competitors are moving — coverage is increasingly a recruiting-page line item, checkable in ten minutes of benchmarking; and utilization is manageable — prior-auth criteria, dose-proof cash-parity negotiations, and program-based delivery cap exposure, which is the committee's real fear. What honesty forbids: promising the employer net savings on a timeline — the peer-reviewed cost-offset literature is younger than the enthusiasm — so the strong version of the case is cost-managed access to standard-of-care, not a fictional ROI spreadsheet. Committees can smell the difference, and the honest frame survives their actuary.
Meanwhile: the cash bridge
Coverage lanes run in quarters; therapy runs in weeks. The bridge: the audited cash floors — $119 semaglutide, $139 tirzepatide, dose-proof and all-in — with HSA/FSA pre-tax treatment (itemized receipt + letter of medical necessity at intake) shaving an effective 20–35%. If the employer lane later opens, the switch machinery moves you to covered brand therapy without restarting anything; if it doesn't, you've lost nothing but the wait. The bridge, priced and audited ↗
FAQ
Why doesn't my insurance cover Zepbound or Wegovy?
On most large employer plans, because your employer's self-funded plan design excludes anti-obesity medications — a rewritable policy choice, which makes HR and the benefits committee the real audience.
How do I ask my employer to cover GLP-1s?
Confirm the exclusion in your SPD, submit a written benefits request timed to the plan-design cycle (ideally with colleagues), pursue formulary exceptions with a clinician letter, and ask specifically about wellness-program-based coverage.
What's the strongest argument to a benefits committee?
Cost-managed access to standard-of-care: the plan already pays obesity's downstream claims, competitors are adding coverage, and prior-auth plus program design caps exposure — without promising unproven net savings.
What do I do while waiting on the employer lane?
Bridge on the audited cash floors ($119/$139, dose-proof) with HSA/FSA pre-tax treatment, then switch to covered brand therapy if the lane opens.
Sources
- ERISA self-funded plan structure; SPD and formulary access rights.
- Trial-anchored comorbidity files: SELECT, SURMOUNT-OSA, FLOW.
- Companion tools: appeal-letter anatomy, savings-card decoder, switch guide.